Literature DB >> 9192967

SN-38, a metabolite of the camptothecin derivative CPT-11, potentiates the cytotoxic effect of radiation in human colon adenocarcinoma cells grown as spheroids.

M Omura1, S Torigoe, N Kubota.   

Abstract

BACKGROUND AND
PURPOSE: CPT-11 (7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) is anew semisynthesized derivative of camptothecin. SN-38 (7-ethyl-10-hydroxycamptothecin), a metabolite of CPT-11, plays a key role in the action of CPT-11.
MATERIALS AND METHODS: To determine whether SN-38 potentiates the cytotoxic effect of radiation, we investigated the interaction of SN-38 and radiation in vitro in monolayer cultures and multicellular spheroids of HT-29 human colon adenocarcinoma cells.
RESULTS: HT-29 spheroids were more resistant to both SN-38 and irradiation than monolayer cells. SN-38 at a concentration of 2.5 microg/ml, which by itself was not cytotoxic, greatly increased the lethal effects of radiation in spheroids, but not in monolayer cultures. Exposure to SN-38 following irradiation inhibited the potentially lethal damage repair (PLDR) in spheroids. It is suggested that the mechanism of the radiosensitization by SN-38 is due to the PLDR inhibition.
CONCLUSIONS: These results indicate that CPT-11 may play a role as radiosensitizer and that a combination of CPT-11 and irradiation could prove to be a particularly effective strategy with which to treat human colon adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9192967     DOI: 10.1016/s0167-8140(97)01924-5

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  7 in total

1.  Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414).

Authors:  Michael B Tomblyn; Bryan H Goldman; Charles R Thomas; Jacqueline K Benedetti; Heinz-Josef Lenz; Vivek Mehta; Thaddeus Beeker; Philip J Gold; James L Abbruzzese; Charles D Blanke
Journal:  J Thorac Oncol       Date:  2012-05       Impact factor: 15.609

2.  Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.

Authors:  Nicholas W Choong; Everett E Vokes; Daniel J Haraf; Peter K Tothy; Mark K Ferguson; Kristen Kasza; Charles M Rudin; Philip C Hoffman; Stuart A Krauss; Livia Szeto; Ann M Mauer
Journal:  J Thorac Oncol       Date:  2008-01       Impact factor: 15.609

3.  Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM.

Authors:  Kurt A Jaeckle; Karla V Ballman; Caterina Giannini; Paula J Schomberg; Matthew M Ames; Joel M Reid; Renee M McGovern; Stephanie L Safgren; Evanthia Galanis; Joon H Uhm; Paul D Brown; Julie E Hammack; Robert Arusell; Daniel A Nikcevich; Roscoe F Morton; Donald B Wender; Jan C Buckner
Journal:  J Neurooncol       Date:  2010-01-09       Impact factor: 4.130

4.  A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.

Authors:  R Glynne-Jones; S Falk; T S Maughan; H M Meadows; D Sebag-Montefiore
Journal:  Br J Cancer       Date:  2007-01-30       Impact factor: 7.640

5.  Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer.

Authors:  G Klautke; P Feyerherd; K Ludwig; F Prall; T Foitzik; R Fietkau
Journal:  Br J Cancer       Date:  2005-04-11       Impact factor: 7.640

6.  SN38-loaded <100 nm targeted liposomes for improving poor solubility and minimizing burst release and toxicity: in vitro and in vivo study.

Authors:  Yi-Ping Fang; Chih-Hung Chuang; Yi-Jhun Wu; Hsin-Che Lin; Yun-Chi Lu
Journal:  Int J Nanomedicine       Date:  2018-05-10

7.  Phase 1/2 study of concurrent chemoradiotherapy with weekly irinotecan hydrochloride for advanced/recurrence uterine cancer: A multi-institutional study of Kansai Clinical Oncology Group.

Authors:  Satoshi Takeuchi; Haruo Kuroboshi; Taisuke Mori; Kimihiko Ito; Eiji Kondo; Tsutomu Tabata; Yoshio Itani; Ryuji Kawaguchi; Kyosuke Takeuchi; Toshinori Soejima; Ryohei Sasaki
Journal:  Chin J Cancer Res       Date:  2020-04       Impact factor: 5.087

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.